长期阿奇霉素减少重症哮喘流感嗜血杆菌并增加耐药
该研究基于AMAZES试验,对61例持续未控制哮喘患者配对痰标本分析,发现48周口服阿奇霉素虽不改变总细菌载量(P=0.37),但显著降低流感嗜血杆菌载量(P<0.0001)和Faith系统发育多样性(P=0.026),并增加大环内酯和四环素耐药基因。
要点
- 阿奇霉素显著降低持续未控制哮喘患者痰流感嗜血杆菌载量。
- 总细菌载量无变化,但细菌多样性下降且耐药基因增加。
- 长期大环内酯治疗需权衡获益与耐药风险。
核心结论
- 在持续未控制哮喘患者中,阿奇霉素较安慰剂降低气道流感嗜血杆菌载量,但不改变总细菌载量。
- 大环内酯耐药增加,与既往研究一致,提示需评估非抗生素大环内酯的长期疗效。
研究设计与样本
- AMAZES试验为48周双盲安慰剂对照试验,成人持续未控制哮喘患者每周三次口服阿奇霉素500 mg。
- 对61例患者配对痰标本(安慰剂34例,阿奇霉素27例)行16S rRNA测序和定量PCR。
- 采用混合模板鸟枪法宏基因组测序、定量PCR和分离株全基因组测序评估耐药。
主要发现
- 阿奇霉素未影响细菌载量(P=0.37),但显著降低Faith系统发育多样性(P=0.026)和流感嗜血杆菌载量(P<0.0001)。
- 对肺炎链球菌、金黄色葡萄球菌、铜绿假单胞菌或卡他莫拉菌载量无显著影响。
- 检测到的89个耐药基因中,5个大环内酯耐药基因和2个四环素耐药基因显著增加。
关键数值与推荐
- 阿奇霉素组27例、安慰剂组34例,共61例配对痰标本。
- 阿奇霉素用法为每周三次口服500 mg,持续48周。
- 细菌载量P=0.37,Faith系统发育多样性P=0.026,流感嗜血杆菌载量P<0.0001。
临床怎么用
- 对持续未控制哮喘患者,长期阿奇霉素可减少流感嗜血杆菌载量但需监测大环内酯耐药。
- 临床决策应权衡减少急性发作的获益与耐药基因增加的风险。
局限性
- 配对痰标本仅来自61例患者,样本量有限。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The macrolide antibiotic azithromycin reduces exacerbations in adults with persistent symptomatic asthma. However, owing to the pleotropic properties of macrolides, unintended bacteriological consequences such as augmented pathogen colonization or dissemination of antibiotic-resistant organisms can occur, calling into question the long-term safety of azithromycin maintenance therapy.Objectives: To assess the effects of azithromycin on the airway microbiota, pathogen abundance, and carriage of antibiotic resistance genes.Methods: 16S rRNA sequencing and quantitative PCR were performed to assess the effect of azithromycin on sputum microbiology from participants of the AMAZES (Asthma and Macrolides: The Azithromycin Efficacy and Safety) trial: a 48-week, double-blind, placebo-controlled trial of thrice-weekly 500 mg oral azithromycin in adults with persistent uncontrolled asthma. Pooled-template shotgun metagenomic sequencing, quantitative PCR, and isolate whole-genome sequencing were performed to assess antibiotic resistance.Measurements and Main Results: Paired sputum samples were available from 61 patients (n = 34 placebo, n = 27 azithromycin). Azithromycin did not affect bacterial load (P = 0.37) but did significantly decrease Faith's phylogenetic diversity (P = 0.026) and Haemophilus influenzae load (P < 0.0001). Azithromycin did not significantly affect levels of Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, or Moraxella catarrhalis. Of the 89 antibiotic resistance genes detected, five macrolide resistance genes and two tetracycline resistance genes were increased significantly.Conclusions: In patients with persistent uncontrolled asthma, azithromycin reduced airway H. influenzae load compared with placebo but did not change total bacterial load. Macrolide resistance increased, reflecting previous studies. These results highlight the need for studies assessing the efficacy of nonantibiotic macrolides as a long-term therapy for patients with persistent uncontrolled asthma.
引用
- Taylor SL, Leong LEX, Mobegi FM, et al. Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. Am J Respir Crit Care Med. 2019. PMID: 30875247. doi:10.1164/rccm.201809-1739OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。